Conference Coverage

Teleconference is effective in assessing penicillin allergy


 

REPORTING FROM AAAAI/WAO JOINT CONGRESS


“This is so overlabeled,” Dr. Ramsey said. “Ten percent of the population thinks they’re allergic to penicillin, and 90% of them are not.”

A stark difference was found in the types of medicines administered before and after the evaluations, with aminopenicillin therapy jumping from 0 days of use to 188 days, and vancomycin – a more potent, but more costly alternative – dropping from 130 days of use to 16 days (P less than .05 for both).

Dr. Ramsey noted that, in part because of the time-consuming nature of the penicillin skin tests, they often are simply not done, so the false allergy labels are not caught, leading to pointless costs and exposure to more potent and potentially harmful forms of antibiotic therapy.

“Some hospitals don’t have allergists who will come in to do testing,” she said. “Sometimes patients are on medications that may interfere. And then a lot of times it’s just underrecognized – the implications of a penicillin allergy label. That is a very hot topic in our field and also in infectious disease.”

Recommended Reading

Repeat blood cultures not useful in treating Gram-negative bacteremia
MDedge Infectious Disease
Adjuvant-boosted shingles vaccine earns FDA panel’s unanimous nod
MDedge Infectious Disease
Climate change may lead to more cellulitis
MDedge Infectious Disease
Concerning rise of staphylococcal scalded skin syndrome has U.S. doctors on alert
MDedge Infectious Disease
Mississippi has highest varicella vaccination rate
MDedge Infectious Disease
FDA approves topical antibiotic for impetigo infections
MDedge Infectious Disease
VIDEO: With tinea capitis, don’t be fooled by a Wood’s lamp
MDedge Infectious Disease
VIDEO: The return of Kaposi’s sarcoma
MDedge Infectious Disease
ALT-70 score outperformed thermal imaging for cellulitis diagnosis
MDedge Infectious Disease
VIDEO: Device-based therapy for onychomycosis
MDedge Infectious Disease